MX350875B - Formas de dosificacion farmaceutica de liberacion controlada. - Google Patents
Formas de dosificacion farmaceutica de liberacion controlada.Info
- Publication number
- MX350875B MX350875B MX2013010987A MX2013010987A MX350875B MX 350875 B MX350875 B MX 350875B MX 2013010987 A MX2013010987 A MX 2013010987A MX 2013010987 A MX2013010987 A MX 2013010987A MX 350875 B MX350875 B MX 350875B
- Authority
- MX
- Mexico
- Prior art keywords
- dosage forms
- controlled release
- pharmaceutical dosage
- release pharmaceutical
- layer
- Prior art date
Links
- 239000002552 dosage form Substances 0.000 title abstract 3
- 238000013270 controlled release Methods 0.000 title 1
- 239000013543 active substance Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2893—Tablet coating processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161467824P | 2011-03-25 | 2011-03-25 | |
| PCT/IB2012/000595 WO2012131463A2 (en) | 2011-03-25 | 2012-03-22 | Controlled release pharmaceutical dosage forms |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013010987A MX2013010987A (es) | 2014-10-13 |
| MX350875B true MX350875B (es) | 2017-09-19 |
Family
ID=46018006
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013010987A MX350875B (es) | 2011-03-25 | 2012-03-22 | Formas de dosificacion farmaceutica de liberacion controlada. |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20140056979A1 (enExample) |
| EP (1) | EP2688556B1 (enExample) |
| JP (1) | JP5964940B2 (enExample) |
| KR (1) | KR101619579B1 (enExample) |
| CN (1) | CN103547259A (enExample) |
| AU (1) | AU2012235878B2 (enExample) |
| BR (1) | BR112013024585A8 (enExample) |
| CA (1) | CA2831218C (enExample) |
| CY (1) | CY1116579T1 (enExample) |
| DK (1) | DK2688556T3 (enExample) |
| ES (1) | ES2544735T3 (enExample) |
| HR (1) | HRP20150835T1 (enExample) |
| HU (1) | HUE026981T2 (enExample) |
| IL (1) | IL228441B (enExample) |
| ME (1) | ME02189B (enExample) |
| MX (1) | MX350875B (enExample) |
| PH (1) | PH12013501994A1 (enExample) |
| PL (1) | PL2688556T3 (enExample) |
| PT (1) | PT2688556E (enExample) |
| RS (1) | RS54152B1 (enExample) |
| SI (1) | SI2688556T1 (enExample) |
| SM (1) | SMT201500209B (enExample) |
| WO (1) | WO2012131463A2 (enExample) |
| ZA (1) | ZA201307862B (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100889069B1 (ko) | 1999-10-29 | 2009-03-17 | 유로-셀티크 소시에떼 아노뉨 | 서방성 하이드로코돈 제형 |
| US10179130B2 (en) | 1999-10-29 | 2019-01-15 | Purdue Pharma L.P. | Controlled release hydrocodone formulations |
| BR0115382A (pt) | 2000-10-30 | 2003-09-16 | Euro Celtique Sa | Formulações para liberação controlada de hidrocodona, método de produzir analgesia efetiva, processo de preparação de uma forma farmacêutica de um sólido oral de liberação controlada, liberação controlada da forma farmacêutica oral e uso da forma farmacêutica |
| WO2003024430A1 (en) | 2001-09-21 | 2003-03-27 | Egalet A/S | Morphine polymer release system |
| EP2957281A1 (en) | 2001-09-21 | 2015-12-23 | Egalet Ltd. | Polymer release system |
| ATE495732T1 (de) | 2003-03-26 | 2011-02-15 | Egalet As | Morphin-system mit kontrollierter freisetzung |
| EP2155167A2 (en) | 2007-06-04 | 2010-02-24 | Egalet A/S | Controlled release pharmaceutical compositions for prolonged effect |
| EP2393484A1 (en) | 2009-02-06 | 2011-12-14 | Egalet Ltd. | Immediate release composition resistant to abuse by intake of alcohol |
| EP2445487A2 (en) | 2009-06-24 | 2012-05-02 | Egalet Ltd. | Controlled release formulations |
| CN104873455B (zh) | 2010-12-22 | 2023-09-12 | 普渡制药公司 | 包覆的抗篡改控制释放剂型 |
| PH12013501345A1 (en) | 2010-12-23 | 2022-10-24 | Purdue Pharma Lp | Tamper resistant solid oral dosage forms |
| IN2014DN09238A (enExample) | 2012-04-17 | 2015-07-10 | Purdue Pharma Lp | |
| KR20150059167A (ko) | 2012-07-06 | 2015-05-29 | 에갈렛 리미티드 | 제어된 방출을 위한 남용 제지 약학적 조성물 |
| SG11201506064UA (en) | 2013-02-05 | 2015-08-28 | Purdue Pharma Lp | Tamper resistant pharmaceutical formulations |
| US10751287B2 (en) | 2013-03-15 | 2020-08-25 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
| AU2014306759B2 (en) | 2013-08-12 | 2018-04-26 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
| WO2015095391A1 (en) | 2013-12-17 | 2015-06-25 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| WO2016010771A1 (en) | 2014-07-17 | 2016-01-21 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
| US9132096B1 (en) | 2014-09-12 | 2015-09-15 | Alkermes Pharma Ireland Limited | Abuse resistant pharmaceutical compositions |
| US9849124B2 (en) | 2014-10-17 | 2017-12-26 | Purdue Pharma L.P. | Systems and methods for treating an opioid-induced adverse pharmacodynamic response |
| CA2964628A1 (en) | 2014-10-20 | 2016-04-28 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
| US9839212B2 (en) | 2015-04-16 | 2017-12-12 | Bio-Lab, Inc. | Multicomponent and multilayer compacted tablets |
| BR112019027889A2 (pt) | 2017-06-30 | 2020-07-07 | Purdue Pharma L.P. | método de tratamento e formas de dosagem do mesmo |
| EP3675842A4 (en) * | 2017-08-31 | 2021-05-19 | Purdue Pharma L.P. | PHARMACEUTICAL DOSAGE FORMS |
| AU2018390826B2 (en) | 2017-12-20 | 2024-09-12 | Purdue Pharma L.P. | Abuse deterrent morphine sulfate dosage forms |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR950007907B1 (ko) * | 1992-09-01 | 1995-07-21 | 동국제약 주식회사 | 치주질환 치료용 막형 국소약물송달제제 |
| US5567439A (en) * | 1994-06-14 | 1996-10-22 | Fuisz Technologies Ltd. | Delivery of controlled-release systems(s) |
| US5634702A (en) | 1995-09-27 | 1997-06-03 | Fistonich; Juraj | Hands free waste container having a closed cover that automatically opens when the container is moved outside its cabinet enclosure |
| PT1251832E (pt) * | 2000-02-04 | 2007-01-31 | Depomed Inc | Forma de dosagem constituída por invólucro-e-núcleo que conduz a uma libertação do fármaco de ordem zero |
| BR0115382A (pt) * | 2000-10-30 | 2003-09-16 | Euro Celtique Sa | Formulações para liberação controlada de hidrocodona, método de produzir analgesia efetiva, processo de preparação de uma forma farmacêutica de um sólido oral de liberação controlada, liberação controlada da forma farmacêutica oral e uso da forma farmacêutica |
| JP5259183B2 (ja) * | 2004-07-01 | 2013-08-07 | グリューネンタール・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 乱用に対して保護された経口剤形 |
| US7434308B2 (en) * | 2004-09-02 | 2008-10-14 | International Business Machines Corporation | Cooling of substrate using interposer channels |
| CA2605180A1 (en) * | 2005-04-19 | 2006-10-26 | Alza Corporation | Controlled delivery dosage form of tramadol and gabapentin |
| WO2007133150A1 (en) * | 2006-05-17 | 2007-11-22 | Sandvik Intellectual Property Ab | A top hammer rock-drilling tool, a drill rod and coupling sleeve |
| SA07280459B1 (ar) * | 2006-08-25 | 2011-07-20 | بيورديو فارما إل. بي. | أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني |
| US8241993B2 (en) * | 2007-07-13 | 2012-08-14 | Marvell World Trade Ltd. | Method for shallow trench isolation |
| AU2009223061B2 (en) * | 2008-03-11 | 2014-10-09 | Depomed Inc. | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
| CN101933907A (zh) * | 2009-06-30 | 2011-01-05 | 北京天衡药物研究院 | 新型骨架缓释片及其制备方法 |
-
2012
- 2012-03-22 PT PT127174688T patent/PT2688556E/pt unknown
- 2012-03-22 HR HRP20150835TT patent/HRP20150835T1/hr unknown
- 2012-03-22 EP EP20120717468 patent/EP2688556B1/en active Active
- 2012-03-22 BR BR112013024585A patent/BR112013024585A8/pt not_active Application Discontinuation
- 2012-03-22 KR KR1020137027839A patent/KR101619579B1/ko active Active
- 2012-03-22 AU AU2012235878A patent/AU2012235878B2/en active Active
- 2012-03-22 HU HUE12717468A patent/HUE026981T2/en unknown
- 2012-03-22 DK DK12717468.8T patent/DK2688556T3/en active
- 2012-03-22 US US14/004,857 patent/US20140056979A1/en not_active Abandoned
- 2012-03-22 SI SI201230275T patent/SI2688556T1/sl unknown
- 2012-03-22 WO PCT/IB2012/000595 patent/WO2012131463A2/en not_active Ceased
- 2012-03-22 CA CA2831218A patent/CA2831218C/en active Active
- 2012-03-22 PH PH1/2013/501994A patent/PH12013501994A1/en unknown
- 2012-03-22 PL PL12717468T patent/PL2688556T3/pl unknown
- 2012-03-22 JP JP2014500486A patent/JP5964940B2/ja active Active
- 2012-03-22 ES ES12717468.8T patent/ES2544735T3/es active Active
- 2012-03-22 MX MX2013010987A patent/MX350875B/es active IP Right Grant
- 2012-03-22 RS RS20150515A patent/RS54152B1/sr unknown
- 2012-03-22 ME MEP-2015-116A patent/ME02189B/me unknown
- 2012-03-22 CN CN201280020303.9A patent/CN103547259A/zh active Pending
-
2013
- 2013-09-15 IL IL228441A patent/IL228441B/en active IP Right Grant
- 2013-10-22 ZA ZA2013/07862A patent/ZA201307862B/en unknown
-
2015
- 2015-08-03 CY CY20151100677T patent/CY1116579T1/el unknown
- 2015-09-09 SM SM201500209T patent/SMT201500209B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2831218A1 (en) | 2012-10-04 |
| WO2012131463A2 (en) | 2012-10-04 |
| ZA201307862B (en) | 2014-06-25 |
| CN103547259A (zh) | 2014-01-29 |
| BR112013024585A8 (pt) | 2018-01-09 |
| PT2688556E (pt) | 2015-09-11 |
| CA2831218C (en) | 2017-01-17 |
| IL228441B (en) | 2019-05-30 |
| JP5964940B2 (ja) | 2016-08-03 |
| PH12013501994A1 (en) | 2013-12-02 |
| ME02189B (me) | 2016-02-20 |
| WO2012131463A3 (en) | 2012-11-29 |
| AU2012235878B2 (en) | 2015-10-15 |
| KR101619579B1 (ko) | 2016-05-10 |
| ES2544735T3 (es) | 2015-09-03 |
| HUE026981T2 (en) | 2016-08-29 |
| HRP20150835T1 (hr) | 2015-09-11 |
| EP2688556A2 (en) | 2014-01-29 |
| EP2688556B1 (en) | 2015-05-06 |
| DK2688556T3 (en) | 2015-08-03 |
| IL228441A0 (en) | 2013-12-31 |
| SI2688556T1 (sl) | 2015-09-30 |
| US20140056979A1 (en) | 2014-02-27 |
| RS54152B1 (sr) | 2015-12-31 |
| JP2014510094A (ja) | 2014-04-24 |
| SMT201500209B (it) | 2015-10-30 |
| AU2012235878A1 (en) | 2013-05-02 |
| KR20130135973A (ko) | 2013-12-11 |
| NZ616600A (en) | 2015-07-31 |
| CY1116579T1 (el) | 2017-03-15 |
| PL2688556T3 (pl) | 2015-10-30 |
| MX2013010987A (es) | 2014-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12013501994A1 (en) | Controlled release pharmaceutical dosage forms | |
| MX2013008737A (es) | Formas de dosificacion oral para tasocitinib que comprende liberacion modificada. | |
| PH12014502462A1 (en) | Complement pathway modulators and uses thereof | |
| WO2012174158A3 (en) | Administration of benzodiazepine | |
| WO2014002051A3 (en) | Complement pathway modulators and uses thereof | |
| WO2014002058A3 (en) | Complement pathway modulators and uses thereof | |
| PH12016500072B1 (en) | Piperidinyl-indole derivatives complement factor b inhibitors and uses thereof | |
| WO2014009833A3 (en) | Complement pathway modulators and uses thereof | |
| CL2013002504A1 (es) | Preparacion farmaceutica solida recubierta que comprende a lo menos un ingrediente activo y porque el recubrimiento tiene un espesor de 0,1 a 100nm, de preferencia de 0,3 a 50 nm y mas preferentemente de 0,5 a 35 nm; y su metodo de preparacion | |
| PH12014501984A1 (en) | Pharmaceutical compositions comprising metformin and a dpp-4 inhibitor or a sglt-2 inhibitor | |
| JO2858B1 (en) | Pharmaceutical dosage images | |
| MY163083A (en) | Solid forms of a pharmaceutically active substance | |
| PH12013501842A1 (en) | Pharmaceutical compositions comprising metformin and a dpp-4 inhibitor or a sglt-2 inhibitor | |
| MX359288B (es) | Forma iv del clorhidrato de ivabradina. | |
| CL2014000849A1 (es) | Compuestos derivados de benzilindazoles sustituido, inhibidores de la quinasa bub1; procedimiento de fabricacion; composicion farmaceutica; combinacion farmaceutica; y su uso en el tratamiento de enfermedades hiperproliferativas. | |
| EP3513789A3 (en) | Prophylactic and therapeutic agents for fgfr3 diseases | |
| MY176793A (en) | Pharmaceutical tablet comprising acetylsalicylic acid and clopidogrel | |
| IN2014MN02236A (enExample) | ||
| PH12013502325A1 (en) | Drug delivery system | |
| EA201400737A1 (ru) | Система доставки на основе множества пеллет с немедленным высвобождением активного вещества | |
| PH12015500653B1 (en) | Combination drug comprising gemigliptin and metformin, and method for the preparation thereof | |
| MX360235B (es) | Composicion para evitar o tratar osteoporosis y metodo de manufactura para el mismo. | |
| MX2016006738A (es) | Procedimiento para producir material particulado inorganico. | |
| MX372834B (es) | PREPARACION FARMACEUTICA COMBINADA QUE COMPRENDE EL BLOQUEANTE DEL RECEPTOR DE LA ANGIOTENSINA II Y EL INHIBIDOR DE LA HMG-CoA REDUCTASA. | |
| GEP201706614B (en) | Compounds, pharmaceutical compositions and a method for the prophylaxis and treatment of the adhesion process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |